<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422171</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.379</org_study_id>
    <secondary_id>2020-A00494-35</secondary_id>
    <nct_id>NCT04422171</nct_id>
  </id_info>
  <brief_title>A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar</brief_title>
  <acronym>Rhoneswitch</acronym>
  <official_title>A 12-month Real Life Study of IBD Patients Under Stable Steroid Free Clinical and Biological Remission Switched From Adalimumab Originator Humira® to One of Its Biosimilar: Amgevita®,Hulio®,Hyrimoz® or Imraldi®.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biosimilars represent great potential in cost saving and reinvestment opportunities in&#xD;
      healthcare. Biosimilars of adalimumab appear to be clinically equivalent to the reference&#xD;
      product in patients with rheumatoid arthritis and psoriasis. No data are currently available&#xD;
      in IBD patients. Real-life data are needed.&#xD;
&#xD;
      Minimizing the switch back is another clinical challenge in the current area of biosimilars.&#xD;
      The primary objective of Rhoneswitch is to describe the magnitude of patient's switch back&#xD;
      defined as a deterioration of symptoms without objective identification of disease activity,&#xD;
      12 months after the switch from ada originator Humira®.&#xD;
&#xD;
      The primary endpoint is to assess the percentage of patients who switch back to originator&#xD;
      therapy Humira® 12 months after switching from ada Humira® to ada Bs: Amgevita® ,Hulio®,&#xD;
      Hyrimoz® or Imraldi® in IBD patients without any objective markers of inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject will be include during usual hospital consultation after reviewing&#xD;
      inclusion/exclusion criteria and obtain non opposition. Data will be collected during 3 usual&#xD;
      hospital consultations: at month 3, month 6, and month 12. The end of study will be at month&#xD;
      12 or at premature termination.&#xD;
&#xD;
      Questionnaires will be done in addition during all usual hospital consultations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of patient's switch back defined as a deterioration of symptoms without objective identification of disease activity, 12 months after the switch from ada originator Humira®.</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients who switch back to originator therapy Humira® 12 months after switching from ada Humira® to ada Bs: Amgevita® ,Hulio®, Hyrimoz® or Imraldi® in IBD patients without any objective markers of inflammation.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>IBD Patients, Originator Treatment, Biosimilar, Switch Back</condition>
  <eligibility>
    <study_pop>
      <textblock>
        IBD Patients (Ulcerative Colitis and Crohn's disease) under stable (more than 3 months)&#xD;
        steroid free clinical and biological remission with adalimumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Documented diagnosis of CD or UC established on the basis of standard clinical,&#xD;
             endoscopic and histological criteria at least 3 months prior to inclusion.&#xD;
&#xD;
          -  Inactive CD or UC outpatients are defined per clinical assessment as an Harvey&#xD;
             Bradshaw Index (HBI) score ≤4 for CD patients and a Partial Mayo Score (PMS) ≤2 with&#xD;
             each sub-score of 1 or less for UC and/or according to ECCO classification (Sturm&#xD;
             2019) within previous 3 months, demonstrating an adequate clinical remission to ada&#xD;
             originator&#xD;
&#xD;
          -  May be receiving the following drugs (but must remain on stable dose for 10 weeks):&#xD;
&#xD;
               -  Oral 5-aminosalicylates (ASA) compounds or rectal formulations of 5ASA provided&#xD;
                  the dose to be stable at least 4 weeks before switching&#xD;
&#xD;
               -  Azathioprine, 6-MP or methotrexate provided the dose has been stable for 4 weeks&#xD;
                  prior to inclusion (dose must remain stable for 10 weeks after switching)&#xD;
&#xD;
          -  Non opposition required&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Diagnosis of indeterminate colitis, ischaemic colitis, fulminant colitis&#xD;
&#xD;
          -  Current use of another TNF inhibitor included (but not limited to) infliximab,&#xD;
             certolizumab, golimumab&#xD;
&#xD;
          -  Current use of vedolizumab or ustekinumab&#xD;
&#xD;
          -  Current use of JAK inhibitors or S1P modulators&#xD;
&#xD;
          -  Current use of oral corticosteroids&#xD;
&#xD;
          -  Active flaring CD or UC patients defined as a HBI &gt; 4 for CD and a PMS&gt;1 for UC and/or&#xD;
             concomitant CS medication&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Subject under guardianship or subject deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Mathieu</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NICOLAS MATHIEU</last_name>
    <phone>+ 33 4 76 76 55 97</phone>
    <email>nmathieu@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure Bordy</last_name>
    <phone>+ 33 4 76 76 61 50</phone>
    <email>lbordy@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MATTHIEU</last_name>
      <email>NMathieu@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MATHIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

